Welcome to our dedicated page for CODEXIS SEC filings (Ticker: CDXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Codexis, Inc. filings document the company's public-company disclosures as a Nasdaq-listed biotechnology issuer focused on enzymatic solutions for therapeutics manufacturing. Recent 8-K reports furnish quarterly and annual operating results, financial-condition updates, business-update exhibits, and material event disclosures tied to organizational streamlining and the ECO Synthesis platform.
Proxy materials describe annual meeting voting, board classes and committee membership, director elections, executive compensation, and other governance matters. The filing record also identifies Codexis common stock, par value $0.0001 per share, trading under CDXS on the Nasdaq Global Select Market.
Codexis, Inc. is reported to have a significant ownership position held by Telemark Asset Management, LLC, Telemark Fund, LP and Colin S. McNay, who jointly report beneficial ownership of 7,846,411 shares of Codexis common stock. This represents 7.3% of the outstanding common shares, with all such shares subject to shared voting and shared dispositive power and no sole voting or dispositive power reported.
The ownership percentage is calculated based on 107,561,409 shares of Codexis common stock outstanding, as referenced in a final prospectus supplement dated July 24, 2026. The reporting entities are organized in Delaware, and Mr. McNay is a United States citizen. A joint filing agreement among the reporting persons is referenced as an exhibit.
Codexis, Inc. entered into an Underwriting Agreement with Piper Sandler & Co. and Cantor Fitzgerald & Co. to issue and sell 16,666,667 shares of its common stock in a public offering at $1.50 per share. The underwriters received a 30-day option to purchase up to 2,500,000 additional shares. The transaction was conducted under the company’s effective shelf registration statement on Form S-3 via a prospectus supplement.
The offering closed on July 27, 2026, when Codexis completed the sale and issuance of the 16,666,667 shares and received net proceeds of approximately $23.1 million after underwriting discounts, commissions and estimated expenses. Codexis, along with all directors and executive officers, agreed to a 90-day lock-up on sales or transfers of common stock after July 23, 2026, subject to specified exceptions.
Codexis, Inc. is conducting a primary offering of 16,666,667 shares of common stock at $1.50 per share, for gross proceeds of $25,000,000.50. Underwriters receive $0.09 per share in underwriting discounts and commissions, with Codexis expecting net proceeds of approximately $23.1 million after fees and expenses.
The company has granted underwriters a 30-day option to purchase up to 2,500,000 additional shares; if fully exercised, gross proceeds would be $28,750,000.50 and net proceeds about $26.6 million. Net proceeds are intended for working capital and general corporate purposes, including research, development and business activities, and potentially acquisitions or investments.
Codexis reports preliminary, unaudited total revenue of at least $14.8 million for the quarter ended June 30, 2026 and cash, cash equivalents and short-term investments of approximately $54.9 million as of that date. As of March 31, 2026, net tangible book value was $40.8 million, or $0.45 per share; after this offering it would have been about $63.8 million, or $0.59 per share, implying immediate dilution of $0.91 per share to new investors.
Codexis, Inc. is conducting a primary offering of common stock under its existing shelf registration, with Piper Sandler, Cantor Fitzgerald and Craig-Hallum as underwriters and a 30‑day option for the underwriters to purchase additional shares. The company’s common stock trades on Nasdaq under “CDXS,” and the last reported sale price was $2.06 per share on July 22, 2026. This sale will provide cash directly to Codexis.
Codexis reports preliminary, unaudited total revenue of at least $14.8 million for the quarter ended June 30, 2026 and expects $54.9 million in cash, cash equivalents and short‑term investments as of that date. As of March 31, 2026, it had 90,894,742 shares outstanding and a net tangible book value of $40.8 million, or $0.45 per share, meaning new investors will experience immediate dilution relative to the offering price.
The company uses its proprietary CodeEvolver directed evolution platform to engineer enzymes for small‑molecule pharmaceutical manufacturing and its ECO Synthesis platform for RNA interference therapeutics manufacturing. Net proceeds are intended for working capital and general corporate purposes, including research, development and business activities, with broad management discretion. Codexis does not expect to pay cash dividends and highlights risks including dilution from this and future equity offerings, potential stock price pressure from additional share sales, and uncertainty about maintaining an active trading market.
Codexis, Inc. expects to report total revenue of at least $14.8 million for the three months ended June 30, 2026, and cash, cash equivalents and short-term investments of approximately $54.9 million as of June 30, 2026. These figures are described as preliminary estimates based on information currently available.
The company notes that these amounts are unaudited and remain subject to completion of financial closing procedures and management review, so actual results for the quarter could differ. Codexis also states that its independent registered public accounting firm has not audited, reviewed, compiled or performed procedures on this preliminary information, and highlights the forward-looking nature of these estimates and related risks referenced in prior SEC filings.
Aberdeen Group plc and its subsidiary abrdn Inc. report beneficial ownership of common stock of Codexis, Inc. (par value $0.0001 per share).
They collectively report beneficial ownership of 6,769,954 shares, representing 7.45% of this class. Both entities report no sole voting or dispositive power, but shared voting and shared dispositive power over all 6,769,954 shares. Aberdeen Group plc is the parent of abrdn Holdings Limited, which is the intermediate holding company for abrdn Inc., and abrdn Inc. holds these shares on behalf of underlying clients.
Codexis, Inc. reported the final voting results from its 2026 Annual Meeting of Stockholders held on June 17, 2026. Stockholders elected Stephen G. Dilly, Raymond De Vré, and Rahul Singhvi as directors for three-year terms expiring at the 2029 annual meeting.
Stockholders also ratified the selection of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 74,561,400 votes for, 106,175 against, and 70,905 abstentions. In addition, they approved, on a non-binding advisory basis, the compensation of the company’s named executive officers.
CODEXIS, INC. director Parker H. Stewart reported receiving a stock option award for 66,350 shares of common stock. The option has an exercise price of $2.48 per share and expires on June 17, 2036, with 66,350 derivative securities held after the grant.
According to the terms, the option vests and becomes exercisable for all 66,350 shares on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to his continued service as a director on that vesting date.
CODEXIS, INC. director Cynthia Collins received a grant of stock options covering 66,350 shares of common stock at an exercise price of $2.48 per share. The options vest in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, and expire in 2036.
CODEXIS, INC. director Christos Richards received a grant of stock options covering 66,350 shares of common stock at an exercise price of $2.48 per share. The options were awarded at no cost, vesting in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to his continued board service, and will expire on June 17, 2036.